Growth Drivers
What could change its growth trajectory, and what would confirm it?
SomnoMed's growth trajectory hinges on North America, its primary growth driver, which posted $45.8 million in FY26 revenue, up 11% at constant currency and 6% on a reported basis. Virtus is a purpose-built option for patients with obstructive sleep apnea and co-existing sleep bruxism.
SomnoMed added more than 20% manufacturing capacity during FY26 and more than 40% over the last two years. The company's plan targets high single digit revenue growth in FY27.
Market Outlook
Is its category moving in its favor or against it?
The oral appliance category is expanding: the global sleep apnea oral appliances market reached USD 728.03 million in 2024 and is forecast to hit USD 1855.08 million by 2030, a compound annual growth rate of 16.9% between 2025 and 2030, supporting demand for SomnoMed's devices. As of October 2024, the National Council on Aging estimated that almost 39 million US adults have OSA and an estimated 936 million adults worldwide have mild to severe OSA, a large population underlying that demand.
Regional differences in regulatory approvals and compliance standards, including FDA 510(k) clearance, CE marking under the European Medical Device Regulation, and Health Canada licensing, create challenges for global market entry. In May 2022, ProSomnus Holdings acquired Lakeshore Acquisition through a business combination that resulted in ProSomnus.
Product Overview
What does the product do for its buyer, and how is it delivered?
SomnoMed's sleep apnea oral appliance is an FDA-cleared, custom-fitted dental device that treats the condition by advancing the lower jaw during sleep to keep the airway open, giving patients an alternative to CPAP therapy.
A sleep dentist creates the fit by scanning or molding impressions and then orders the device. SomnoMed's b-flex Comfort Liner adds a soft lining found only on its oral appliances.
